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Cardiovascular safety of SGLT2 inhibitors
AbSTrACT
Sodium-glucose co-transporter-2 (SGLT2) inhibitors, 
also called flozins, are a new group of oral antidiabetic 
drugs. Due to progressive nature of type 2 diabetes 
and gradual deterioration of pancreatic beta cell func-
tion, achieving good diabetes control still remains a 
challenge. This stimulates researchers and clinicians to 
search for new directions in diabetes treatment and 
to develop optimal antidiabetic therapy. Particularly 
interesting in this context are (besides incretin-based 
therapies) SGLT2, because they reduce renal glucose 
reabsorption and, thereby, increase urinary glucose 
excretion. Their action is independent from an insulin, 
both in terms of an insulin secretion and action. Type 2 
diabetes remains one of the major cardiovascular 
risk factors. The most important issue related to this 
group of drugs is therefore establishing the princi-
ples of safe, well-tolerated and effective long-term 
treatment of patients with vascular complications of 
various severity, including cardiovascular complica-
tions mainly. New antidiabetic drugs should not only 
improve glycaemic control, but also contribute to the 
reduction of cardiovascular morbidity and mortality. 
(Clin Diabet 2016; 5, 2: 62–65)
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Despite large-scale preventive interventions, 
diabetes remains a significant public health problem 
that becomes increasingly important both from clini-
cal and epidemiological point of view and efforts to 
achieve a therapeutic goal established individually for 
each patient, besides the normalization of increased 
blood pressure, coexisting lipid disorders and excessive 
body weight, are key elements of the treatment. From 
the patient’s point of view, optimal diabetes therapy 
should be based on a simple regimen of drugs that are 
effective and safe and have no adverse effects. Due 
to progressive nature of type 2 diabetes and gradual 
deterioration of pancreatic beta cell function, achiev-
ing good diabetes control still remains a challenge. 
This stimulates researchers and clinicians to search for 
new solusions in diabetes treatment and to develop 
optimal antidiabetic therapy. Particularly interesting 
in this context are (besides incretin-based therapies) 
sodium-glucose co-transporter-2 (SGLT2) inhibitors, 
because they reduce renal glucose reabsorption and, 
thereby, increase urinary glucose excretion. Their ac-
tion is independent from an insulin, both in terms of 
an insulin secretion and action. Thereby, the level of 
coexisting insulin resistance and/or pancreatic beta cell 
dysfunction related to the progressive nature of the dis-
ease do not influence the effectiveness of the therapy, 
which allows for additional beneficial and long-term 
effect of SGLT2 inhibitors on glycaemic control, and 
this effect is independent from the stage of the natural 
history of diabetes.
SGLT2 proteins, a group of type 2 sodium-depend-
ent glucose transporters, are localised in the kidneys, 
within the brush border of the proximal tubular seg-
ment S1 of the nephron, and have a low affinity but 
high capacity for glucose, and under physiological 
condition they are responsible for 90% of glucose 
reabsorption [1]. 
Contemporary SGLT2 inhibitors are derivatives of 
phlorizin, an agent that was first isolated in 1835 from 
the root bark of the apple tree and was initially used 
as an antipyretic and for the treatment of infections. 
Stimulating effect of phlorizin on renal excretion of 
glucose has been discovered later, in the second half 
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of the 19th century. Its activity in human kidneys has 
been shown in 1933, but its antidiabetic effect has been 
discovered quite recently — in 1987; and only from that 
time on researchers’ interests have been focused on 
this new potential mechanism of anti-hyperglycaemic 
activity in type 2 diabetes [2]. 
Despite considerable progress in medicine, intro-
ducing new classes of glucose-lowering drugs and 
improving the methods of blood glucose monitoring, 
the development of late vascular complications (mainly 
cardiovascular ones) remains the most important 
problem of contemporary diabetology, leading to 
substantial reduction of patients’ life expectancy and 
quality of life. 
Available data indicate a close relationship between 
the level and duration of hyperglycaemia and the risk of 
late vascular complications of diabetes. Therefore, ef-
forts to achieve blood glucose normalization, alongside 
the treatment of blood lipids disorders, body mass and 
blood pressure reduction, according to the guidelines 
on multidirectional, comprehensive approach to the 
treatment of diabetes, is of key importance in the 
prevention and slowing the progression of vascular 
complication. This has been evidenced by the results of 
large clinical trials such as DCCT (Diabetes Control and 
Complications Trial) for type 1 diabetes or UKPDS (UK 
Prospective Diabetes Study) for type 2 diabetes. Based 
on detailed analysis of the results of above-mentioned 
trials, as well as the results of the STENO and STENO-2 
trials and the large clinical trials performed in 2008 
— ACCORD (Action to Control Cardiovascular Risk in 
Diabetes), ADVANCE (Action in Diabetes and Vascular 
Disease-Preterax and Diamicron Modified Release Con-
trolled Evaluation) and VADT (Veterans Affairs Diabetes 
Trial) — it can be concluded that striving for optimal 
glucose control is not beneficial for all patients with 
type 2 diabetes. Such approach proved to be the saf-
est and most effective in patients with newly detected 
diabetes or in those with short disease duration and 
good metabolic control who did not develop macroan-
giopathic complications [3–11].
Type 2 diabetes still remains one of the most 
important cardiovascular risk factors. Cardiovascular 
complications are responsible for about 65% deaths in 
diabetic patients. At the same time, about 60% of pa-
tients diagnosed with stable or unstable coronary artery 
disease (CAD) have glucose metabolism disturbances, 
such as impaired fasting glucose (IFG), IGT or overt type 
2 diabetes. Additionally, diabetes has been diagnosed in 
20–45% of clinical trial participants, including patients 
hospitalized for acute coronary syndrome (ACS), who 
had no history of diabetes. In this group of patients, 
diabetes is more prevalent in women than in men (41.6 
vs. 30.7%). Many years ago, in 1998, the study results 
were published that suggested that diabetes should be 
regarded as a coronary heart disease (CHD) equivalent. 
The increase in cardiovascular risk in diabetic patients 
is caused not only by diabetes per se, but also by the 
presence of other cardiovascular risk factors overlap-
ping with carbohydrate metabolism disorders [12–14].
Therefore, establishing the principles for long-term, 
safe, well-tolerated and effective therapy in patients 
with diabetes complications of various severities 
(mainly cardiovascular ones) is a significant issue related 
to the new classes of drugs. New antidiabetic drugs 
should not only influence glycaemic control, but also 
contribute to decrease in cardiovascular morbidity and 
mortality in patients with type 2 diabetes. Taking the 
above into account, in December 2008 Science Board 
of the Food and Drug Administration (FDA) issued 
a guidance requiring the assessment of cardiovascular 
risk for all new molecules used for the treatment of 
type 2 diabetes. This guidance specifies methodology of 
clinical trials and registration of cardiovascular events. It 
is recommended that these trials should be performed 
among diabetic patients with increased cardiovascular 
risk, in patients aged > 65 years, and in patient with 
kidney dysfunction, assuming the follow-up period of 
≥ 2 years [15].
These trials are designed to show that the use of 
antidiabetic drugs as one of the standard option for 
the treatment of diabetes is not associated with the 
increase in cardiovascular risk (cardiovascular safety) 
compared with placebo. However, it should be high-
lighted that they are not designed to show cardio-
vascular benefits resulting from the improvement of 
metabolic control and HbA1c reduction. Cardiovascular 
safety and cardiovascular benefits should be assessed 
regardless of the HbA1c reduction [15].
SGLT2 inhibitors, also called flozins, are the newest 
group of oral antidiabetic drugs. Their mechanism of 
action is based on the inhibition of glucose reabsorp-
tion leading to its urinary excretion of 50–80 grams 
per day, which is equivalent to 200–320 kcal per day. 
These drugs improve glycaemic control, both in fasting 
as well as in postprandial state. As mentioned above, 
this effect is independent from an insulin, both in terms 
of its secretion and action, and, importantly, can be 
achieved with the low risk of hypoglycaemia. Benefits 
from treatment with SGLT2 inhibitors are not limited 
to improvement in the parameters of carbohydrate 
metabolism control. Negative energy balance results in 
body weight reduction and, subsequently, has favour-
able effect on insulin sensitivity and, through additional 
decrease in glucotoxicity, potential beta cell protective 
effect. Additionally, SGLT2 inhibitors decrease both sys-
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tolic and diastolic blood pressure which are significant 
and well-established cardiovascular risk factors. Avail-
able results of the clinical trials show favourable effect 
of this class of drugs on plasma lipoproteins reflected 
in decreased LDL-cholesterol and triglycerides as well 
as increased HDL-cholesterol, decreased serum level 
of uric acid, inhibition of renin-angiotensin axis and 
decreased oxidative stress [1, 16–26].
There are three SGLT2 inhibitors available in Poland: 
dapagliflozin (Forxiga, AstraZeneca), canagliflozin (In-
vokana, Janssen-Cilag) and empagliflozin (Jardiance, 
Boehringer Ingelheim). All of them offer unique benefits 
for type 2 diabetes patients beyond the improvement 
of metabolic control.
Effect on body weight
Overweight and obesity are key risk factors for the 
development and progression of type 2 diabetes, but 
also cardiovascular diseases per se. SGLT2 inhibitors 
cause reduction of both visceral and subcutaneous 
fatty tissue, which consequently results in body mass 
reduction [16–21, 23].
Hypotensive effect
Beneficial effect of SGLT2 inhibitors on systolic and 
diastolic blood pressure results, to some extent, from 
body mass reduction and subsequent improvement of 
insulin sensitivity; but first of all it is a consequence of 
increased sodium excretion in response to volume load 
and increased serum sodium level as well as osmotic 
diuresis accompanying urinary elimination of glucose. 
Meta-analysis of 25 RCT concerning this issue showed 
that there is a reduction in systolic blood pressure by 
4.0 mm Hg and diastolic blood pressure by 1.6 mm Hg 
from baseline values [16–21, 23–28].
Antiatherogenic effect
SGLT2 inhibitors, likewise incretin-based drugs, have 
beneficial effect on independent cardiovascular risk fac-
tors. Besides glucose level fluctuations, in patients with 
diabetes these factors include obesity and associated 
insulin resistance, lipid disorders, hypertension and el-
evated serum level of uric acid. All these factors increase 
oxidative stress and induce epithelial dysfunction [29].
Impact on cardiovascular risk
Registration trials of SGLT2 inhibitors have proven 
favourable cardiovascular profile of these drugs, but 
the results of landmark EMPA-REG OUTCOME trial pub-
lished on September 17, 2015 may establish a turning 
point in the treatment of type 2 diabetes (if the results 
of ongoing trials with other drugs from this group 
confirm previous data). 
The EMPA-REG OUTCOME® trial, a long-term clini-
cal trial aimed to assess the effect of the therapy with 
empagliflozin on cardiovascular outcomes in patients 
with type 2 diabetes with high risk of cardiovascular 
events, is the first trial that showed unequivocally that 
this drug added to glucose lowering therapy signifi-
cantly reduced the risk of cardiovascular episodes. Im-
portantly, the trial was designed specifically to evaluate 
such results. In this trial, 7020 patients who fulfilled 
inclusion criteria were randomised on a basis 1:1:1 to 
standard antidiabetic therapy or to empagliflozin 10 or 
25 mg daily on top of standard antidiabetic therapy. The 
median observation time was 3.1 years. Primary com-
posite endpoint was defined as time to first occurrence 
of death from cardiovascular causes, nonfatal myocar-
dial infarction or nonfatal stroke. Secondary composite 
endpoint was defined as time to first occurrence of 
death from cardiovascular causes, nonfatal myocardial 
infarction or nonfatal stroke and, additionally, hospital-
ization for unstable angina. During observation, there 
was a significant reduction in primary endpoint (10.5% 
vs. 12.1%) in the empagliflozin group compared with 
placebo group, with relative risk reduction (RRR) of 
its occurrence by 14% (HR 0.86; 95% CI 0.74–0.99; 
p = 0.04). Moreover, there was a significant risk reduction 
in the rates of death from cardiovascular causes by 38% 
(HR 0.62; 95% CI 0.49–0.77; p = 0.001), hospitalization 
for heart failure by 35% (HR 0.65; 95% CI 0.50–0.85; 
p = 0.002) and death from any cause by 32% (HR 0.68; 
95% CI 0.57–0.82; p = 0.001).
The study also showed a 11% reduction in second-
ary composite endpoint (12.8% vs. 14.3%) in the group 
treated with empagliflozin compared with placebo 
group (HR 0.89; 95% CI 0.78–1.01; p < 0.001 for non-
inferiority and p = 0.08 for superiority). It is important 
and noteworthy that the rates of adverse events (AEs) 
and serious adverse events (SAE) leading to discontinu-
ation of the participation in the study were similar in 
the group treated with empagliflozin and the group 
receiving placebo, and that the percentages of patients 
with ketoacidosis, volaemic disturbances, thromboem-
bolic episodes and bone fractures were low — not more 
than 1% for ketoacidosis and thromboembolic events 
and 5% for volaemic disturbances [30].
In summary, it should be highlighted that SGLT2 
inhibitors are effective in reducing HbA1c, both in 
monotherapy and in combination with other oral glu-
cose-lowering drugs and/or insulin, and offer benefits 
for patients with type 2 diabetes extending consider-
ably beyond the impact on glycaemic control. Based 
on the analysis of available data from clinical trials, it 
may be stated that these drugs reduce body weight, 
systolic and diastolic blood pressure, have favourable 
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effect on lipid parameters, uric acid level and RA axis 
activity and have nephroprotective effect, however 
subsequent trials with SGLT2 inhibitors are needed 
to establish whether promising results of EMPA-REG 
OUTCOME® trial are only unique for empagliflozin or 
are the effect of the class.
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